ELEMENTS FOR ECONOMIC EVALUATION ON ONLINE HEMODIAFILTRATION (OL-HDF) VERSUS STANDARD HAEMODIALYSIS TO TREAT PATIENTS WITH END-STAGE RENAL DISEASE (ESRD)

Considering the additional direct costs of on-line HDF therapy compared to HD Low-flux, its technological maturity, its increasing utilization in Europe it is clear that those costs are more than offset by the decrease in drug consumption and hospitalization rates, justifying the higher reimbursement for on-line HDF compared to other HD modalities. In order to increase the utilization and dissemination of this technology, this slightly higher reimbursement should be introduced without limiting it to a specific patient population.